ALFA Finder| Revenue growth | 23% YoY for FY26; 5% YoY for 4Q FY26. |
|---|---|
| Margins | FY26 Gross Margins 60.4% (+500bps); EBITDA margins 26.8% (+670bps). |
| Order book | Active projects in CDMO increased to 125 (up from 110). |
| Demand visibility | Strong CDMO demand; ARV leadership maintained with steady demand outlook. |
| Management confidence | High; emphasis on transformation and value creation over 20 years. |
Growth
FY26 Revenue reached ₹6,813 Cr (+23%); EBITDA at ₹1,826 Cr (+64%) with 26.8% margins; PAT at ₹889 Cr (+148%).
Outlook
₹3000 Cr capex for growth projects; >$600mn 8-year investment plan for new 532-acre Vizag site; interim dividend of ₹1.20/share.
Risks
Global supply chain disruptions persist; high R&D intensity; concentration in ARV segment though de-risking is underway.
Earnings Call filed with NSE, NSE: LAURUSLABS. Summary written with AI assistance from the document.
Laurus Labs Ltd: key numbers
- Share price
- ₹2,412.50
- Market cap
- ₹1,30,350 Cr
- Revenue (annual)
- ₹6,813 Cr
- Net profit (annual)
- ₹888.8 Cr
- P/E (TTM)
- 97.3×Sector 43.8×
- Promoter holding
- 27.47%+0.00% QoQ
- FII holding
- 30.84%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Laurus Labs Ltd
All →Laurus Labs Earnings Call Transcript: Key Takeaways
Laurus Labs delivered record revenue driven by CDMO strength and API growth. While margins improved through operating leverage, high capex continues to constrain free cash flow.
Laurus Labs Results Update
Laurus Labs reported H1 FY27 revenue of ₹4,233 Cr and EBITDA of ₹1,406 Cr. The company acquired Galenvs Sciences and SI&C Resins to expand CDMO capabilities.
- SPPS peptide synthesis capacity
- 16000 L
Laurus Labs Investor Presentation: Key Takeaways
Q2/H1 FY27: H1 revenue ₹4,233 Cr (+31%), EBITDA ₹1,406 Cr (33.2% margin), PAT ₹809 Cr (+126%). CDMO-led growth; ₹3,000 Cr+ capex planned FY27-28.
Laurus Labs Dividend
Laurus Labs approved a Re. 1.00 per share interim dividend for FY 2026-27. Record date is November 6, 2026; payment on or after November 19, 2026.
Laurus Labs Management Change
Laurus Labs appointed Mr. Kundan Kumar Jha as Joint Company Secretary effective November 1, 2026, following Board approval. The KMP appointment advances the company's succession planning process.
Laurus Labs Acquisition Worth ₹32.5 Cr
Laurus Labs approved acquiring 52% of SI & C Resins for Rs. 32.50 Crore. The acquisition makes SI&C a subsidiary for peptide resin manufacturing.
- Value
- ₹32.50 Cr